Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (141963)	2/10/2005 10:07:35 AM
From: dkgross	Respond to of 150070

whaaaaatttttt :) damn..sold too soon. poopy.

To: Jim Bishop who wrote (141963)	2/10/2005 11:05:28 AM
From: buylow_sellhigh	Read Replies (1) \| Respond to of 150070

JB, GTEL looks to be holding its own here. Summit conference in 11 days.

To: Jim Bishop who wrote (141963)	2/10/2005 11:26:32 AM
From: Supervalue	Read Replies (1) \| Respond to of 150070

GTEL doing much wonder if GLBT would coat tail

To: Jim Bishop who wrote (141963)	2/11/2005 2:08:00 PM
From: StocksDATsoar	Respond to of 150070

Glaxo is suing La Mesa firm over Nicodrops Thursday , February 10, 2005 08:27 ET By Penni Crabtree Feb 10, 2005 (The San Diego Union-Tribune - Knight Ridder/Tribune Business News via COMTEX) --British drug giant GlaxoSmithKline filed a federal lawsuit this week to stop a La Mesa company from claiming its herbal product helps smokers quit. Glaxo's Consumer Healthcare subsidiary, which makes the branded NicoDerm patch and Nicorette gum, is seeking an injunction against Nicodrops Inc., alleging the La Mesa company is making false claims about the safety and efficacy of its herbal lozenges, Nicodrops. "Quitting smoking is one of the most important steps smokers can take to improve their health, but it's very hard to do," said George Quesnelle, president of GSK Consumer Healthcare. "When people are misled into using snake oil instead of products that are proven to work, they waste a critical opportunity to quit smoking and potentially save their own lives. "We simply want Nicodrops to stop making false claims about their products and ours, and to withdraw their products from the marketplace until they can market them truthfully." In a written statement yesterday, Nicodrops chief executive Christopher Calpito said the lawsuit "has absolutely no basis." "Nicodrops looks forward to dealing with it in court," Calpito said. "We are intent on vigorously defending our company and its products." On Nicodrops' Web site, which features pictures of young women in tight T-shirts and shorts, the company says it offers the only "drug-free solution to stop smoking." It says its product was developed at a clinical laboratory to "harness the cause of nicotine addiction." A one-month supply of the herbal lozenges, which contain ginseng, valerian and St. John's Wort, is $59.70, according to the Web site. The company said it spent 11 years in research and development of the product but does not offer any research or clinical trial data on its Web site to support claims that the product has been proven safe and effective. Nicodrops does takes aim at its better-known rivals: "While our competitors continue to use nicotine in their products, our lozenges offer a much safer and effective alternative as well as being less expensive," according to the Web site. For Glaxo, those are fighting words. In a written statement, Glaxo said there is "no proof that any herbal ingredient in Nicodrops, or the Nicodrops product itself, is a safe or effective therapy for smoking cessation." Under federal law governing dietary supplements, herbal products don't have to be tested for safety or health benefits before they are sold. But it is unlawful for such products to make druglike health claims of curing or treating a medical condition. "Nicodrops and any other products making health claims as a drug should be subject to the same rigorous Food and Drug Administration review process as GSK Consumer Healthcare's nicotine replacement therapies, which are proven to help smokers quit," Glaxo said. The Glaxo lawsuit, filed in federal district court in Pennsylvania, also seeks a retraction of "false" information published by Nicodrops about GSK Consumer Healthcare's products. Nicodrops Inc. is a so-called pink sheet company whose stock trades over the counter. The company's shares closed yesterday at 1.7 cents, up two-tenths of a cent. To see more of The San Diego Union-Tribune, or to subscribe to the newspaper, go to uniontrib.com.